Personalizing CLL Treatment Options: Clinical Insights and Strategies to Improve Care

This comprehensive program gathers CLL management insights from our distinguished CLL experts and features education on emerging and established treatment strategies enhanced by a decision support tool for individualizing these treatments to your patients. All aspects of this program are designed to complement each other including the interactive treatment decision aid expert commentaries and an expert-authored module with downloadable slideset.

Share

Program Content

Activities

First- vs Second-Gen BTKi
How I Use First-Generation vs Second-Generation BTK Inhibitors in CLL and MCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2018

Expires: April 12, 2019

R/R CLL: Venetoclax + R
How I Use Venetoclax/Rituximab in Relapsed/Refractory CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2018

Expires: July 23, 2019

PI3K Inhibitors in CLL
The Role of First-Generation vs Second-Generation PI3K Inhibitors in CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2018

Expires: September 12, 2019

CLL Online Tool
An Interactive Online Tool Featuring Expert Recommendations for CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 10, 2018

Expires: October 09, 2019

Activities

Future in CLL: Slides
Future Directions in CLL Therapy: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2018

Expires: September 30, 2019

Activities

CLL Roundtable Video
An Expert Roundtable Exploring Breakthroughs and Challenges in Chronic Lymphocytic Leukemia Care
Congratulations: You achieved a completion on 04/09/2022
CLL Slides
An Expert Roundtable Exploring Breakthroughs and Challenges in Chronic Lymphocytic Leukemia Care
Case Challenge
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 27, 2018

Expires: June 26, 2019

CLL: AEs With Novel Agents
Personalizing CLL Treatment Options: Managing Adverse Events Associated With Novel Agents
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2018

Expires: July 23, 2019

CLL: Current Challenges
Personalizing CLL Treatment With Targeted Therapies: Clinical Insights on New and Emerging Strategies
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2018

Expires: August 20, 2019

Faculty

cover img faculity

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio

cover img faculity

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

cover img faculity

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

cover img faculity

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Acerta Pharma AstraZeneca Group

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company